Peginterferon beta-1a - Biogen

Drug Profile

Peginterferon beta-1a - Biogen

Alternative Names: BIIB 017; PEG-interferon-β-1a; PEGylated INF-beta-1a - Biogen; Plegridy

Latest Information Update: 06 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biogen Idec
  • Developer Biogen
  • Class Interferons; Neuroprotectants
  • Mechanism of Action Immunomodulators; Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 04 Apr 2018 Biogen has patent protection for peginterferon beta-1a in USA and Europe
  • 23 Oct 2017 Eisai and Biogen agree to co-promote Peginterferon beta-1a in India and other Asia-Pacific countries
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top